AI Generated Image
A 3-Year-Old's Metastatic Cancer Disappeared After Two Doses of Experimental Therapy
Yahoo • • health
Key Points:
- A three-year-old boy with chemotherapy-resistant hepatoblastoma, a malignant liver cancer, achieved complete tumor regression after receiving an experimental CAR T cell therapy targeting glypican-3 (GPC3), as reported in The New England Journal of Medicine.
- The therapy involved genetically engineering the boy's own T cells to recognize GPC3 and included genes for interleukin–15 and interleukin–21 to enhance the immune cells' longevity and tumor-killing ability.
- After two infusions of the GPC3-CAR treatment, the patient showed no signs of cancer for at least 12 months, marking a significant breakthrough in using CAR T cell therapy for solid tumors.
- This case highlights the potential of CAR T cell therapy as a safe and effective treatment for hepatoblastoma and other GPC3-positive solid tumors, though further clinical trials are needed to confirm these findings.
- The CARE study at Baylor College of Medicine and the IMPACT trial at Seattle Children's Hospital are ongoing to evaluate the broader effectiveness and safety of this novel immunotherapy approach.
